Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 14 Lymphoma, Non-Hodgkin 10 Carcinoma, Non-Small-Cell Lung 7 Breast Neoplasms 7 Arthritis, Rheumatoid 7 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, B-Cell 5 Lymphoma 5 Solid Tumors 4 Recurrence 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasms 4 Melanoma 4 Leukemia, Myeloid, Acute 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Colorectal Neoplasms 4 Ovarian Neoplasms 3 Lymphoma, Follicular 3 Leukemia 3 Hematologic Neoplasms 3 Cytokine Release Syndrome 3 Burkitt Lymphoma 3 Urinary Bladder Neoplasms 2 Respiratory Distress Syndrome 2 Pancreatic Neoplasms 2 Myelodysplastic Syndromes 2 Lymphoma, Mantle-Cell 2 Fallopian Tube Neoplasms 2 Craniopharyngioma 2 Carcinoma, Hepatocellular 2

Interventions

tocilizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unresectable Pancreatic Carcinoma × tocilizumab × Clear all

NCT02767557 2023-09-22

PACTO

Herlev Hospital

Phase 2 Completed

Gastrointestinal

Unresectable Pancreatic Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡